WolverHeme Happy Hour

This is a special encore video presentation of Anthony and Bernie teaming up with the Common Sense Oncology Journal Club series to discuss the SWOG1826 and STARGLO clinical trials. Tycel Phillips, MD, and Manju Sengar, MD join Anthony and Bernie for a great discussion of the trials and how they should impact practice! Join the Common Sense Oncology movement here! https://commonsenseoncology.org/

Joining the discussion are Victoria Nachar, an outpatient hematology pharmacist from the University of Michigan with expertise in lymphoma and myeloma, and James Davis, a malignant hematology pharmacist and assistant professor at MUSC, known for his deep knowledge in multiple myeloma. They explore the management of cytokine release syndrome (CRS) in patients receiving bispecific antibodies, comparing it to CAR-T therapies. They discuss current treatment strategies, the role of prophylactic tocilizumab, and the importance of tailored approaches in patient care.

Join Dr. Anand Patel, a hematology MD and leading educator, alongside Dr. Charlie Foucar, a brilliant hematologist, as they delve into the controversial journey of gemtuzumab in treating acute myeloid leukemia (AML). They discuss its dramatic rise and fall, backed by intriguing studies and data interpretations. Hear them analyze treatment outcomes and dosing strategies while unpacking biases in clinical research. Their engaging banter, peppered with humor and personal anecdotes, makes complex medical discussions entertaining and enlightening!

Join Julia Brown, PharmD, a pediatric hematology/oncology pharmacist, and Lydia Benitez, an adult leukemia pharmacist, as they dive into the evolving landscape of blinatumomab in acute lymphoblastic leukemia (ALL). They discuss the impactful findings of the AALL1731 trial and ECOG-1910, shedding light on improved survival rates. The conversation touches on practical challenges like home infusion, patient monitoring strategies, and the exciting potential of subcutaneous formulations, all while emphasizing equitable access for vulnerable populations.

AQUILA is a constellation shaped like an eagle, and also a hotly debated myeloma trial of daratumumab in smoldering multiple myeloma. In this episode, Bernie and Anthony are joined by myeloma expert Manni Mohyuddin to discuss the study's findings and whether or not they should change practice! Grab a drink and listen in for an exciting discussion. Note: L'aquila is Italian for eagle! AQUILA: Dimopoulos MA, et al. N Engl J Med. 2024 Dec 9. doi: 10.1056/NEJMoa2409029. Epub ahead of print. PMID: 39652675.

In this episode released just in time for the holidays, Anthony and Bernie are joined by Tycel Phillips, MD to discuss the most exciting updates from ASH 2024 in lymphoma! Pour yourself a drink and have a listen! Some selected abstracts: EA4151: https://ash.confex.com/ash/2024/webprogram/Paper212973.html Triangle Updates: https://ash.confex.com/ash/2024/webprogram/Paper200735.html , https://ash.confex.com/ash/2024/webprogram/Paper201441.html EA4181: https://ash.confex.com/ash/2024/webprogram/Paper194641.html ENRICH: https://ash.confex.com/ash/2024/webprogram/Paper199710.html inMIND: https://ash.confex.com/ash/2024/webprogram/Paper212970.html POLARIX Long-Term F/U: https://ash.confex.com/ash/2024/webprogram/Paper197938.html

In this episode, Anthony and Bernie are joined by Dr. Aaron "Papa Heme" Goodman and Dr. Manni "Myeloma Man" Mohyuddin to discuss the most intriguing ASH 2024 abstracts! Should any of the research from ASH 2024 change your practice? Find out!

In this episode, Bernie and Anthony are joined by two special guest expert hematologists: Dr. David Russler-Germain Dr. Tycel Phillips We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired? Stay tuned to find out!

In this episode, Tycel Phillips, MD joins Anthony and Bernie to discuss updates in Mantle Cell Lymphoma, including the TRIANGLE study and the recently published results of glofitamab in R/R MCL. TRIANGLE: https://pubmed.ncbi.nlm.nih.gov/38705160/ Glofitamab: https://pubmed.ncbi.nlm.nih.gov/39365960/

In this episode, Anthony and Bernie discuss the recently reported APOLLO trial in high-risk APL and debate whether this should represent the new standard of care in this population. We also review key practical considerations for the treatment of APL patients, including side effect management and treatment of APL in unique clinical scenarios. APOLLO: https://library.ehaweb.org/eha/2024/eha2024-congress/422206/uwe.platzbecker.first.results.of.the.apollo.trial.a.randomized.phase.iii.study.html